期刊文献+

1例肠癌患者应用西妥昔单抗注射液后谷丙转氨酶变化分析 被引量:1

下载PDF
导出
摘要 目的:研究临床试验用药西妥昔单抗注射液1例患者应用后对谷丙转氨酶的影响。方法:晨起嘱患者空腹,采静脉血,带血凝后分离出血清,应用美国进口全自动生化分析DXC800检测肝功谷丙转氨酶,试剂应用美国进口原装配套试剂。结果:该患者应用西妥昔单抗注射液前查肝功谷丙转氨酶正常为22.0U/L,应用3d后查肝功仪器报警为谷丙转氨酶吸光度低,后尝试把血清稀释四倍重新检测谷丙转氨酶为26U/L正常。结论:通过查阅有关于西妥昔单抗注射液文献没有报道西妥昔单抗注射液对患者谷丙转氨酶的影响,所以通过对该例患者谷丙转氨酶检测的分析,为临床试验用药西妥昔单抗注射液的应用提供一些参考资料。
机构地区 吉林省肿瘤医院
出处 《中国当代医药》 2011年第2期145-145,148,共2页 China Modern Medicine
  • 相关文献

参考文献5

  • 1储大同,周继昌.实用肿瘤内科学[M].北京:人民卫生出版社,2005.174~182.
  • 2Cunningham D,Hmut blet Y,Siena S,et aI.Centuximab monothcrapy and Cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer[J].N Engl J Med,200d,351(4):337-345.
  • 3Ciardiello F,Tortota G,Anovel G.Approaeh in the treatment of cancer targeting the epidermal growth factor receptor[J].Clin Cancer Res,2001,7: 2958-2970.
  • 4Venook AP.Epidermal growth factor receptor targeted treatment of for Advanced colorectal carcinoma[J].Cancer,2005,103(2):2435-2446.
  • 5崔岚,逄晓云,王晓珉.新型抗肿瘤药物西妥昔单抗[J].中国药师,2005,8(4):332-334. 被引量:16

二级参考文献13

  • 1Shaheen RM, Ahmad SA, Liu W, et al. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors[J]. Br J Cancer, 2001, 85(4) :584-589.
  • 2Bianco C, Bianco R, Tortora G, et al. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type Ⅰ protein kinase A antisense oligonucleotide[J]. Clin Cancer Res, 2000, 6( 11 ) :4343-4350.
  • 3Shin DM, Donato NJ, Perez-Soler R, et al. Epidermal growth factor receptor -targeted therapy with C225 and cisplatin in patients with head and neck cancer [J]. Clin Cancer Res, 2001,7(5) :1204-1213.
  • 4Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. Phase Ⅱ trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor[J]. J Clin Oncol. 2004, 22(7) :1201-1208.
  • 5Baselga J. The EGFR as a target for anticancer therapy - focus on cetuximab [ J]. Eur J Cancer, 2001,37( Suppl 4) :S16-22.
  • 6Huang SM, Bock JM, Harari RM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck [ J ]. Cancer Res, 1999, 59 ( 8 ): 1935-1940.
  • 7Ciardiello F, Damiano V, Bianco R, et al. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A [ J ]. J Natl Cancer Inst, 1996,88(23) :1770-1776.
  • 8Ciardiello F, Bianco R, Damiano V, et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotde in human GEO colon cancer cells[J]. Clin Cancer Res, 2000, 6(9) :3739-3747.
  • 9Perrotte P, Matsumoto T, Inoue K, et al. Anti-epidermal growth factor receptor cantibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice[J]. Clin Cancer Res, 1999, 5(2) :257-265.
  • 10Robert F, Ezekiel MP, Spencer SA, et al. Phase I studies of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer[ J]. J Clin Oncol, 2001, 19(13) :3234-3243.

共引文献17

同被引文献39

  • 1邵仲英,封宇飞,傅得兴.新型表皮生长因子受体抑制剂——西妥昔单抗[J].中国全科医学,2006,9(4):317-318. 被引量:12
  • 2BLICK SK, SCOTT LJ. Cetuximab: a review of its use insquamous cell carcinoma of the head and neck and metastaticcolorectal cancer[J]. Drugs, 2007, 67(17) : 2585-2607.
  • 3MENDELSOHN J, BASELGA J. Status of epidermal growthfactor receptor antagonists in the biology and treatment of cancer[J]. J Clin Oncol, 2003, 21(14): 2787-2799.
  • 4LI T, PEREZ - SOLER R. Skin toxicities associated withepidermal growth factor receptor inhibitors[J]. Target Oncol, 2009,4(2): 107-119.
  • 5FAKIH M,VINCENT M. Adverse events associated with anti -EGFR therapies for the treatment of metastatic colorectal cancer[J]. Curr Oncol, 2010,17 Suppl 1 : S18-S30.
  • 6MITCHELL EP,PEREZ-SOLER R, VAN CE, et al. Clinicalpresentation and pathophysiology of EGFRI dermatologictoxicities [J]. Oncology (Williston Park),2007, 21 (11 Suppl5): 4-9.
  • 7MAKOTO K, MADOKA S, MEGUMU M,et al. Cetuximab -induced skin reactions are suppressed by cigarette smoking inpatients with advanced colorectal cancer [J]. Int J Clin Oncol,2012[Epub ahead of print].
  • 8OUWERKERK J, BDERS - DOETS C. Best practices in themanagement of toxicities related to anti - EGFK agents formetastatic colorectal cancer[J]. Eur J Oncol Nurs, 2010, 14(4):337-349.
  • 9GARRETT CR, ENG C. Cetuximab in the treatment of patientswith colorectal cancer[J]. Expert Opin Biol Ther, 2011,11(7):937-949.
  • 10GERBER PA, MELLER S., EAMES T, et al. Management ofEGFR - inhibitor associated rash : a retrospective study in 49patients[J]. Eur J Med Res, 2012,17: 4.

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部